Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors

Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors

Bibliographic Details
Main Authors:	Jianbing QIAO, Wenping CHEN
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2011-10-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Lung neoplasms
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2011.10.07

Similar Items

Mechanisms of Acquired Resisitance to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Hongjie LI, et al.
Published: (2009-12-01)

Advanced Research on the Response of EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer Therapy
by: Qiang SONG, et al.
Published: (2009-12-01)

Protein Kinase C Inhibitor and Treatment of Non-Small Cell Lung Cancer
by: Zhiqiang GAO, et al.
Published: (2009-01-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Lianfang NI, et al.
Published: (2018-02-01)

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor  Receptor Mutations in Non-small Cell Lung Cancer
by: Xue YANG, et al.
Published: (2015-08-01)

Mechanisms of Resistance to EML4-ALK Inhibitors in Non-small Cell Lung Cancer
by: Di WU, et al.
Published: (2013-01-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC
by: Recondo, Gonzalo
Published: (2019)

Relationship Between BIM Gene Polymorphism and Therapeutic Efficacy in the  Retreatment of Advanced Non-small Cell Lung Cancer with Tyrosine Kinase Inhibitor
by: Lei ZHENG, et al.
Published: (2013-12-01)

Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted  Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors
by: Guowei ZHANG, et al.
Published: (2017-04-01)

Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them
by: Yunshu SHI, et al.
Published: (2019-05-01)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021-02-01)

The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
by: Baohui HAN, et al.
Published: (2009-12-01)

The Relationship between EGFR Mutations and Response and Prognosis of Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer
by: Xuebing LI, et al.
Published: (2008-04-01)

Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors
by: Wenqiu ZHANG, et al.
Published: (2017-10-01)

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
by: Zhang Lingling, et al.
Published: (2016-01-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Treatment Choice After EGFR-TKI Resistance
by: Junling LI
Published: (2013-10-01)

Application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as the First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer
by: Chunsun LI, et al.
Published: (2010-01-01)

Research Progress of Treatment Strategy for Pulmonary Nodule
by: Feng GAO, et al.
Published: (2013-05-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Protein Kinase CK2 and Human Malignant Tumors
by: Yixuan HUANG, et al.
Published: (2012-07-01)

Current Status and Prospects of Maintenance Therapy in Advanced Stage Non-small Cell Lung Cancer
by: Lin QUAN, et al.
Published: (2010-06-01)

Association between GNAS1 T393C Polymorphism and Therapeutic Efficacy of Tyrosine Kinase Inhibitor in Pretreated Advanced Non-small Cell Lung Cancer with Unknown EGFR Mutation Status
by: Wei HONG, et al.
Published: (2014-04-01)

Research Progress and Application of the Homeodomain-interacting Protein Kinase -2
by: Wenyun JIA, et al.
Published: (2011-04-01)

A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients with Non–Small-Cell Lung Cancer
by: Ramaswamy GOVINDAN
Published: (2010-04-01)

The Biologic Characteristics and Treatment of Non-Small Cell Lung Cancer in Non Smokers
by: Rong QIAO, et al.
Published: (2009-02-01)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang WX, et al.
Published: (2016-01-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
by: Xiaoling Song, et al.
Published: (2021-09-01)

Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors
by: Xiaoyan KANG, et al.
Published: (2016-10-01)

Non-small Cell Lung Cancer Lung Metastasis?  Or the Second (and More) of Primary Lung Cancer  ---- Key Concepts Influencing Treatment Strategies
by: Keneng CHEN
Published: (2014-07-01)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
by: Toshio Fujino, MD, et al.
Published: (2021-03-01)

Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Gergis, Carol
Published: (2019)

Advance on the Role of Mitogen-activated Protein Kinase (MAPK) Signal Pathway in Non-small Cell Lung Cancer
by: Yuhui ZHOU, et al.
Published: (2009-09-01)

Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
by: Shuping XUE, et al.
Published: (2015-10-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
by: Marcin Skrzypski, et al.
Published: (2017-09-01)

Treatment strategies to reverse efflux transporter-mediated resistance to Tyrosine kinase inhibitors
by: D'Cunha, Ronilda Raymond
Published: (2018)

Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib
by: Afua Kunadu, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_pp7pk9shs7e80e1j7ma6rgst20